Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples